Compare Stocks: MREO, IVVD, GALT, and STRO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GALT Galectin Therapeutics	$3.93 -0.3%	$3.79	$2.03 ▼ $7.13	$258.83M	0.38	433,431 shs	69,353 shs
IVVD Invivyd	$0.68 -6.0%	$0.82	$0.53 ▼ $3.07	$199.55M	0.95	4.06 million shs	2.49 million shs
MREO Mereo BioPharma Group	$0.32 -8.5%	$0.31	$0.20 ▼ $2.37	$51.58M	0.2	5.26 million shs	1.12 million shs
STRO Sutro Biopharma	$13.30 -6.8%	$19.20	$7.15 ▼ $43.85	$220.36M	1.49	263,881 shs	227,573 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GALT Galectin Therapeutics	0.00%	+1.03%	+0.77%	-14.35%	-16.53%
IVVD Invivyd	0.00%	-12.27%	-8.19%	-8.42%	-59.02%
MREO Mereo BioPharma Group	0.00%	-7.87%	+24.96%	+9.00%	-82.15%
STRO Sutro Biopharma	0.00%	-7.04%	-15.36%	-48.74%	+77.55%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GALT Galectin Therapeutics	$3.93 -0.3%	$3.79	$2.03 ▼ $7.13	$258.83M	0.38	433,431 shs	69,353 shs
IVVD Invivyd	$0.68 -6.0%	$0.82	$0.53 ▼ $3.07	$199.55M	0.95	4.06 million shs	2.49 million shs
MREO Mereo BioPharma Group	$0.32 -8.5%	$0.31	$0.20 ▼ $2.37	$51.58M	0.2	5.26 million shs	1.12 million shs
STRO Sutro Biopharma	$13.30 -6.8%	$19.20	$7.15 ▼ $43.85	$220.36M	1.49	263,881 shs	227,573 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GALT Galectin Therapeutics	0.00%	+1.03%	+0.77%	-14.35%	-16.53%
IVVD Invivyd	0.00%	-12.27%	-8.19%	-8.42%	-59.02%
MREO Mereo BioPharma Group	0.00%	-7.87%	+24.96%	+9.00%	-82.15%
STRO Sutro Biopharma	0.00%	-7.04%	-15.36%	-48.74%	+77.55%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GALT Galectin Therapeutics	2.00	Hold	$11.00	179.90% Upside
IVVD Invivyd	2.33	Hold	$10.00	1,374.93% Upside
MREO Mereo BioPharma Group	2.13	Hold	$1.67	420.83% Upside
STRO Sutro Biopharma	3.00	Buy	$49.50	272.18% Upside

Current Analyst Ratings Breakdown

Latest MREO, IVVD, GALT, and STRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/30/2026	STRO Sutro Biopharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$49.00
9/29/2026	MREO Mereo BioPharma Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/29/2026	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/16/2026	STRO Sutro Biopharma	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/14/2026	GALT Galectin Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/14/2026	IVVD Invivyd	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/8/2026	IVVD Invivyd	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/7/2026	STRO Sutro Biopharma	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/27/2026	IVVD Invivyd	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/24/2026	IVVD Invivyd	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/19/2026	MREO Mereo BioPharma Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral ➝ Underweight

(Data available from 10/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	($1.99) per share	N/A
IVVD Invivyd	$53.43M	3.74	N/A	N/A	$1.04 per share	0.65
MREO Mereo BioPharma Group	N/A	N/A	N/A	N/A	$0.26 per share	N/A
STRO Sutro Biopharma	$45.70M	4.83	N/A	N/A	($15.43) per share	-0.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GALT Galectin Therapeutics	-$30.84M	-$0.43	N/A	N/A	N/A	N/A	N/A	-176.83%	11/13/2026 (Estimated)
IVVD Invivyd	-$52.49M	-$0.33	N/A	N/A	N/A	-183.90%	-59.73%	-48.97%	11/5/2026 (Estimated)
MREO Mereo BioPharma Group	-$41.88M	-$0.04	N/A	N/A	N/A	N/A	-74.82%	-64.28%	11/9/2026 (Estimated)
STRO Sutro Biopharma	-$191.09M	-$11.97	N/A	N/A	N/A	-395.25%	N/A	-88.12%	11/5/2026 (Estimated)

Latest MREO, IVVD, GALT, and STRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	MREO Mereo BioPharma Group	-$0.01	N/A	N/A	N/A	$4.61 million	N/A
11/5/2026	Q3 2026	IVVD Invivyd	-$0.11	N/A	N/A	N/A	$15.04 million	N/A
11/5/2026	Q3 2026	STRO Sutro Biopharma	-$1.6637	N/A	N/A	N/A	$13.61 million	N/A
8/14/2026	Q2 2026	GALT Galectin Therapeutics	-$0.09	-$0.14	-$0.05	-$0.14	N/A	N/A
8/13/2026	Q2 2026	IVVD Invivyd	-$0.1067	-$0.14	-$0.0333	-$0.14	$14.40 million	$14.29 million
8/12/2026	Q2 2026	MREO Mereo BioPharma Group	-$0.01	-$0.01	N/A	-$0.05	$3.50 million	N/A
8/12/2026	Q2 2026	STRO Sutro Biopharma	-$2.19	-$2.33	-$0.14	-$2.33	$11.96 million	$9.84 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	N/A
IVVD Invivyd	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	N/A	N/A	N/A	N/A	N/A
STRO Sutro Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GALT Galectin Therapeutics	N/A	0.10	0.10
IVVD Invivyd	N/A	5.87	5.87
MREO Mereo BioPharma Group	N/A	5.88	5.88
STRO Sutro Biopharma	N/A	3.32	3.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GALT Galectin Therapeutics	11.68%
IVVD Invivyd	70.36%
MREO Mereo BioPharma Group	62.83%
STRO Sutro Biopharma	96.99%

Insider Ownership

Company	Insider Ownership
GALT Galectin Therapeutics	52.60%
IVVD Invivyd	12.25%
MREO Mereo BioPharma Group	6.50%
STRO Sutro Biopharma	1.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GALT Galectin Therapeutics	9	65.86 million	31.22 million	Optionable
IVVD Invivyd	122	294.76 million	258.65 million	Optionable
MREO Mereo BioPharma Group	39	159.69 million	149.31 million	Optionable
STRO Sutro Biopharma	128	16.58 million	16.28 million	Optionable

MREO, IVVD, GALT, and STRO Headlines

Recent News About These Companies

Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference

2 hours ago | markets.businessinsider.com

Vaxcyte Prices $1 Billion in Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

October 6, 2026 | quiverquant.comQ

Vaxcyte Announces Webcast and Conference Call to Present Topline Data from OPUS-1 Phase 3 Trial of VAX-31 in Adults

October 4, 2026 | quiverquant.comQ

Sutro Biopharma, Inc. (NASDAQ:STRO) Stock Has Average Price Target of $49.50 According to Brokerages

October 4, 2026 | americanbankingnews.com

Sutro Biopharma, Inc. (NASDAQ:STRO) Stock Rated "Buy" by Wall Street Brokerages

October 4, 2026 | marketbeat.com

Wells Fargo & Company Initiates Coverage on Sutro Biopharma (NASDAQ:STRO)

October 2, 2026 | americanbankingnews.com

Sutro Biopharma (NASDAQ:STRO) Coverage Initiated by Analysts at Wells Fargo & Company

September 30, 2026 | marketbeat.com

Sutro Biopharma, Inc. annonce la nomination de Lucas Donigian au poste de vice-président senior chargé du développement commercial, à compter du 28 septembre 2026

September 30, 2026 | zonebourse.comZ

Sutro Biopharma, Inc. Announces Appointment of Lucas Donigian as Senior Vice President, Business Development, Effective September 28, 2026

September 30, 2026 | marketscreener.comM

Sutro Biopharma nomina Lucas Donigian come responsabile dello sviluppo

September 29, 2026 | it.investing.com

Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development

September 29, 2026 | globenewswire.com

Sutro Biopharma (NASDAQ:STRO) Rating Lowered to "Strong Sell" at Wall Street Zen

September 19, 2026 | marketbeat.com

Sutro Biopharma (NASDAQ:STRO) Raised to Strong-Buy at Mizuho

September 18, 2026 | marketbeat.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sutro Biopharma (STRO), Summit Therapeutics (SMMT) and Altimmune (ALT)

August 14, 2026 | theglobeandmail.com

STRO stock plummets 15% — what drove the selloff?

August 12, 2026 | msn.com

Why is Sutro Biopharma Stock Falling On Wednesday?

August 12, 2026 | benzinga.com

Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study

August 12, 2026 | globenewswire.com

News Flash: Analysts Just Made A Massive Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Forecasts

May 28, 2026 | finance.yahoo.com

US$47.10 - That's What Analysts Think Sutro Biopharma, Inc. (NASDAQ:STRO) Is Worth After These Results

May 17, 2026 | finance.yahoo.com

Wedbush upgrades Sutro Biopharma (STRO)

May 16, 2026 | msn.com

Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights

May 14, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MREO, IVVD, GALT, and STRO Company Descriptions

Galectin Therapeutics NASDAQ:GALT

$3.93 -0.01 (-0.25%)

As of 03:21 PM Eastern

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Invivyd NASDAQ:IVVD

$0.68 -0.04 (-5.99%)

As of 03:41 PM Eastern

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Mereo BioPharma Group NASDAQ:MREO

$0.32 -0.03 (-8.55%)

As of 03:40 PM Eastern

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Sutro Biopharma NASDAQ:STRO

$13.30 -0.97 (-6.80%)

As of 03:40 PM Eastern

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MREO, IVVD, GALT, and STRO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MREO, IVVD, GALT, and STRO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MREO, IVVD, GALT, and STRO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MREO, IVVD, GALT, and STRO Company Descriptions

Galectin Therapeutics NASDAQ:GALT

Invivyd NASDAQ:IVVD

Mereo BioPharma Group NASDAQ:MREO

Sutro Biopharma NASDAQ:STRO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MREO, IVVD, GALT, and STRO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MREO, IVVD, GALT, and STRO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MREO, IVVD, GALT, and STRO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MREO, IVVD, GALT, and STRO Company Descriptions

Galectin Therapeutics NASDAQ:GALT

Invivyd NASDAQ:IVVD

Mereo BioPharma Group NASDAQ:MREO

Sutro Biopharma NASDAQ:STRO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools